Curtis A Lachowiez,Sanam Loghavi
Curtis A Lachowiez
Drekolias and colleagues report a therapy-specific prognostic model integrating mutational and cytogenetic features to risk-stratify survival in patients with acute myeloid leukemia treated with venetoclax-based regimens, providing a clinic...
Incorporating ALL Biology into Treatment Decisions: Next Steps toward Targeted Therapy in Adult ALL [0.03%]
Caner Saygin,Matthew T Witkowski,Sinan Cetin et al.
Caner Saygin et al.
Acute lymphoblastic leukemia (ALL) management is evolving from a generalized approach toward a precision medicine paradigm driven by molecular heterogeneity. This review highlights how genomic profiling identifies high-risk subtypes, includ...
Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy [0.03%]
Sofie-Katrin Kadel,Lukas Scheller,Alexander M Leipold et al.
Sofie-Katrin Kadel et al.
We report a fatal case of parkinsonism following treatment with ciltacabtagene autoleucel. To investigate underlying mechanisms, we performed a multi-pronged longitudinal analysis using single-cell RNA/TCR sequencing, flow cytometry, and cy...
Two Costimulations Are Better Than One: Role of Endogenous CD28 in 4-1BB CAR T Cells [0.03%]
两个共刺激优于一个：内源性CD28在4-1BB CAR-T细胞中的作用
Mohamad Hamieh,Michel Sadelain
Mohamad Hamieh
Liberman and colleagues identify endogenous CD28 signaling as a regulator of 4-1BB chimeric antigen receptor (CAR) T-cell function by promoting metabolic fitness, proliferation, and sustained antitumor function. These findings highlight the...
Reading the "T" Leaves: Predicting Outcomes with Bispecific Antibodies in Multiple Myeloma [0.03%]
解读“T” leaves：“双特异性抗体在多发性骨髓瘤中的应用及预测」
Rahul Banerjee,Madhav V Dhodapkar
Rahul Banerjee
In this issue of Blood Cancer Discovery, Frenking and colleagues demonstrate the prognostic potential of three risk score models to predict hematotoxicity, infections, response rates, and survival following bispecific T-cell engager (TCE) t...
Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancers [0.03%]
遗传证据否定B淋巴克隆细胞是浆细胞癌的贮存库
Carmen González,Juan-Jose Garces,Hector Gracia et al.
Carmen González et al.
Whether multiple myeloma (MM) and light-chain amyloidosis (AL) stem from terminally differentiated plasma cells (PC) or earlier clonotypic B cells remains under debate. Addressing this issue would improve accurate diagnosis and treatment mo...
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed Refractory Multiple Myeloma [0.03%]
debulking化疗可以克服Teclistamab对复发难治性多发性骨髓瘤的原发耐药性
Rintu Sharma,Andree-Anne Pelland,Katherine Lajkosz et al.
Rintu Sharma et al.
Bispecific antibodies have revolutionized the treatment of multiple myeloma (MM), however primary treatment failure occurs in 30-40% of patients. In this study, we analyzed correlates of response to teclistamab and strategies to overcome pr...
The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities [0.03%]
淋巴瘤中的B细胞受体图谱：机制和治疗机会
Stefano Casola,Gabriele Varano
Stefano Casola
The B-cell receptor (BCR) is central to normal and malignant B-cell biology, integrating intrinsic programs with microenvironmental cues to shape cell fate. Across mature B-cell lymphomas, differences in BCR expression, class, and signaling...
Multiplexed imaging reveals immune-metabolic niches in multiple myeloma linked to progression and bone disease [0.03%]
多重成像揭示与多发性骨髓瘤进展和骨病相关的免疫代谢生态位
Ingrid Aass Roseth,Lukas Hatscher,Chiara Schiller et al.
Ingrid Aass Roseth et al.
Multiple myeloma (MM) is a plasma cell (PC) cancer that depends on the bone marrow (BM) microenvironment for disease establishment and progression. Here, we spatially mapped BM biopsies from patients with MM, smoldering MM, and monoclonal g...
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapy [0.03%]
用于多发性骨髓瘤患者接受双特异性T细胞活化剂治疗的毒性作用和疗效预测的评分系统
Jan H Frenking,Christine Riedhammer,Thomas Hielscher et al.
Jan H Frenking et al.
The significant clinical benefit of bispecific T-cell engagers (TCEs) for the treatment of relapsed/refractory multiple myeloma (RRMM) may be offset by serious toxicities and treatment failure. Risk scores such as the CAR-HEMATOTOX (HTX), E...